HURA TuHURA Biosciences Inc.

$HURA TuHURA Biosciences Receives Key U.S. Patent for its Groundbreaking Delta Opioid Receptor (DOR) Antibody Drug Conjugate (ADC) Technology

$HURA Two recent U.S. patents expand protection for TBS-2025, our VISTA-inhibiting antibody, and specified uses of DOR antagonists in cancer. Our preclinical ADC approach is designed to link a DOR inhibitor to our VISTA-inhibiting antibody. TBS-2025 also has FDA IND clearance for a Phase 1b study in relapsed or refractory AML with mutated NPM1. The patents help protect potential commercial value across these development paths, including opportunities for future collaboration.

$HURA Our new U.S. patent expands protection for TBS-2025, our VISTA-inhibiting antibody, across specified molecular modifications and treatment uses. This strengthens the IP behind the program and helps protect its potential commercial value as development advances.

$HURA the intismeran autogene news didn’t give a bump to Hura or others in similar immunotherapy space. Why? Intismeran autogene prevents recurrence after the tumor is removed. Perhaps the market thinks unresectable tumors will overwhelm the immune system.

$HURA took a $650,000 draw on its revolving credit facility, adding to the $50 million loan for general corporate purposes.

$HURA With TBS-2025 cleared to advance into a Phase 1b study and IFx-2.0 already in a randomized Phase 3 registration trial, TuHURA now has two distinct clinical development paths focused on resistance to cancer immunotherapy. IFx-2.0 is designed to overcome primary resistance to checkpoint inhibitors and is being evaluated as an adjunct to Keytruda in first-line advanced or metastatic Merkel cell carcinoma. TBS-2025 is designed to inhibit VISTA, a negative immune checkpoint implicated in AML immune escape. Its FDA-cleared Phase 1b path begins in NPM1-mutated AML, while the IND also covers evaluation in molecularly defined subsets of AML and other blood-related cancers. Together, these programs extend TuHURA’s clinical work across solid and blood cancers, with each addressing distinct biology through which cancers resist or evade immune attack.